Home  >  Press Releases  >  Most Recent
Share

Press Releases

Press release year list 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 2008 2007 2006
December 28, 2017
Zoetis Inc . (NYSE:ZTS) will host a webcast and conference call at 8:30 a.m. (ET) on Thursday, Feb. 15, 2018. Chief Executive Officer Juan Ramón Alaix and Executive Vice President and Chief Financial Officer Glenn David will review fourth quarter and full year 2017 financial results and respond to questions from financial analysts during the call. Investors and the public may access the live webcast by visiting the Zoetis website at http://investor.zoetis.com/events-presentations. Information on accessing and pre-registering for the webcast is available beginning today. A replay of the webcast will be made available on Feb. 15, 2018. About Zoetis Zoetis is the leading animal health company, dedicated to supporting its customers and their businesses. Building on more than 60 years of experience in animal health, Zoetis discovers, develops, manufactures and markets veterinary vaccines and medicines, complemented by diagnostic products, genetic tests, biodevices and a range of services. ...
December 13, 2017
Zoetis Inc. (NYSE:ZTS) will participate in the 36th Annual J.P. Morgan Healthcare Conference on Wednesday, Jan. 10, 2018, in San Francisco, Calif. Juan Ramón Alaix, Chief Executive Officer, will represent the company and respond to questions from analysts. He is scheduled to present at 12:30 p.m. EST (9:30 a.m. PST). Investors and other interested parties will be able to access a live audio webcast of the presentation by visiting http://investor.zoetis.com/events-presentations. A replay of the presentation will also be available on the Zoetis website at the conclusion of the event. About Zoetis Zoetis is the leading animal health company, dedicated to supporting its customers and their businesses. Building on more than 60 years of experience in animal health, Zoetis discovers, develops, manufactures and markets veterinary vaccines and medicines, complemented by diagnostic products, genetic tests, biodevices and a range of services. Zoetis serves veterinarians, livestock producers and ...
December 12, 2017
Zoetis today announced the launch of Vanguard ® CIV H3N2/H3N8, the latest vaccine in the company’s canine influenza virus (CIV) portfolio. The new bivalent vaccine helps protect dogs against two strains of the virus known to be circulating in the U.S., CIV H3N2 and CIV H3N8. CIV is a severe and highly contagious respiratory infection that has caused many serious disease outbreaks in 38 states across the country. 1 The United States Department of Agriculture (USDA) granted Zoetis a license for this vaccine in June 2017. “Zoetis is committed to helping protect dogs from all known strains of canine influenza virus, and our new Vanguard CIV H3N2/H3N8 vaccine is the most recent example of our innovation in this area,” said Tara L. Bidgood, DVM, PhD, DACVCP, Executive Director, U.S. Companion Animal Division Veterinary Professional Services at Zoetis. “We are pleased to offer veterinarians this vaccine, which is backed by outstanding safety and efficacy data, so that they can help protect ...
December 11, 2017
The Board of Directors of Zoetis Inc . (NYSE:ZTS) has declared a first quarter 2018 dividend payable to holders of the company’s common stock of $0.126 per share, an increase of 20% from the quarterly dividend rate paid in 2017. The dividend is to be paid on Thursday, March 1, 2018, to holders of record on Friday, January 19, 2018. “In 2017, Zoetis has continued to deliver steady, profitable growth based on our diverse portfolio, improved cost structure and ongoing investments in innovation,” said Juan Ramón Alaix, Chief Executive Officer of Zoetis. “We have been able to improve our cash flow generation based on this performance, and with the Board’s approval, I am pleased to announce that we are once again increasing our dividend - by 20% in 2018 - as part of our commitment to returning excess capital to shareholders.” About Zoetis Zoetis is the leading animal health company, dedicated to supporting its customers and their businesses. Building on more than 60 years of experience in ...
November 2, 2017
Reports Revenue of $1.3 Billion, Growing 9%, and Net Income of $298 Million, or $0.61 per Diluted Share, Growing 25% and 27%, Respectively, on a Reported Basis for Third Quarter 2017 Reports Adjusted Net Income of $322 Million, or Adjusted Diluted EPS of $0.65, for Third Quarter 2017 Delivers 8% Operational Growth in Revenue and 25% Operational Growth in Adjusted Net Income, Excluding Foreign Exchange, for Third Quarter 2017 Raises Full Year 2017 Revenue Guidance to $5.225 - $5.275 Billion and Diluted EPS to $2.16 - $2.23 on a Reported Basis, or $2.34 - $2.39 on an Adjusted Basis Zoetis Inc . (NYSE:ZTS) today reported its financial results for the third quarter of 2017 and raised its full year guidance for revenue and net income. The company reported revenue of $1.3 billion for the third quarter of 2017, an increase of 9% compared with the third quarter of 2016. Net income for the third quarter of 2017 was $298 million, or $0.61 per diluted share, an increase of 25% and 27%, ...
October 6, 2017
Zoetis Inc . (NYSE:ZTS) will participate in the Credit Suisse Healthcare Conference on Tuesday, Nov. 7, 2017, in Scottsdale, Ariz. Executive Vice President and Chief Financial Officer Glenn David, will represent the company and respond to questions from analysts. He is scheduled to present at 11:30 a.m. MT (1:30 p.m. ET). Investors and other interested parties will be able to access a live audio webcast of the presentation by visiting http://investor.zoetis.com/events-presentations. A replay of the presentation will also be available on the Zoetis website at the conclusion of the event. About Zoetis Zoetis is the leading animal health company, dedicated to supporting its customers and their businesses. Building on more than 60 years of experience in animal health, Zoetis discovers, develops, manufactures and markets veterinary vaccines and medicines, complemented by diagnostic products, genetic tests, biodevices and a range of services. Zoetis serves veterinarians, livestock producers ...
October 5, 2017
The Board of Directors of Zoetis Inc . (NYSE:ZTS) has declared a fourth quarter 2017 dividend payable to holders of the company’s common stock of $0.105 per share. The dividend is to be paid on Friday, Dec. 1, 2017, to holders of record on Thursday, Nov. 9, 2017. About Zoetis Zoetis is the leading animal health company, dedicated to supporting its customers and their businesses. Building on more than 60 years of experience in animal health, Zoetis discovers, develops, manufactures and markets veterinary vaccines and medicines, complemented by diagnostic products, genetic tests, biodevices and a range of services. Zoetis serves veterinarians, livestock producers and people who raise and care for farm and companion animals with sales of its products in more than 100 countries. In 2016, the company generated annual revenue of $4.9 billion with approximately 9,000 employees. For more information, visit http://www.zoetis.com/ . DISCLOSURE NOTICES Forward-Looking Statements: This press ...
September 29, 2017
Zoetis Inc . (NYSE:ZTS) will host a webcast and conference call at 8:30 a.m. (ET) on Thursday, Nov. 2, 2017. Chief Executive Officer Juan Ramón Alaix and Executive Vice President and Chief Financial Officer Glenn David will review third quarter 2017 financial results and respond to questions from financial analysts during the call. Investors and the public may access the live webcast by visiting the Zoetis website at http://investor.zoetis.com/events-presentations. Information on accessing and pre-registering for the webcast is available beginning today. A replay of the webcast will be made available on Nov. 2, 2017. About Zoetis Zoetis is the leading animal health company, dedicated to supporting its customers and their businesses. Building on more than 60 years of experience in animal health, Zoetis discovers, develops, manufactures and markets veterinary vaccines and medicines, complemented by diagnostic products, genetic tests, biodevices and a range of services. Zoetis serves ...
September 26, 2017
Zoetis recognized by Working Mother magazine for its work-life programs, paid family leave, back-up child care, and health and wellness benefits for employees Marketing Leader Kim Balaski named Zoetis’ Working Mother of the Year Zoetis Inc . (NYSE:ZTS) today announced that it has been named one of the top ten companies on Working Mother magazine’s "100 Best Companies for Working Mothers" list. The publication selects the top 100 companies in the U.S. that have demonstrated their commitment to progressive workplace programs such as flexibility, advancement, paid family leave and childcare. Zoetis has been included on the list for four consecutive years since becoming a public company in 2013 and among the top ten for three of those years. “We at Zoetis are proud to be honored again as one of Working Mother magazine’s top ten companies,” said Roxanne Lagano, Executive Vice President and Chief Human Resources Officer at Zoetis. “This award has special meaning for us because it continues ...
September 25, 2017
Zoetis Inc . (NYSE:ZTS) will participate in the Cantor Fitzgerald Global Healthcare Conference on Tuesday, Sept. 26, 2017, in New York, N.Y. Juan Ramón Alaix, Chief Executive Officer, will represent the company and respond to questions from analysts. He is scheduled to present at 10:55 a.m. ET. Investors and other interested parties will be able to access a live audio webcast of the presentation by visiting http://investor.zoetis.com/events-presentations. A replay of the presentation will also be available on the Zoetis website at the conclusion of the event. About Zoetis Zoetis is the leading animal health company, dedicated to supporting its customers and their businesses. Building on more than 60 years of experience in animal health, Zoetis discovers, develops, manufactures and markets veterinary vaccines and medicines, complemented by diagnostic products, genetic tests, biodevices and a range of services. Zoetis serves veterinarians, livestock producers and people who raise and ...
September 5, 2017
Zoetis Inc. (NYSE:ZTS) today announced that it has agreed to sell $1.25 billion of senior notes, consisting of $750 million aggregate principal amount of 3.000% senior notes due 2027 and $500 million aggregate principal amount of 3.950% senior notes due 2047, in an underwritten public offering. Zoetis intends to use the net proceeds to repay, prior to maturity, the principal (including a make-whole amount) of its 1.875% senior notes due 2018 in the aggregate principal amount of $750 million; and for general corporate purposes. The offering is expected to close on September 12, 2017, subject to customary closing conditions. Barclays Capital Inc., Citigroup Global Markets Inc., J.P. Morgan Securities LLC, Merrill Lynch, Pierce, Fenner & Smith Incorporated and MUFG Securities Americas Inc. are acting as joint book-running managers of the underwriters. The final prospectus supplement and accompanying prospectus, when available, may be accessed through the SEC’s website at www.sec.gov . ...
August 8, 2017
Reports Revenue of $1.3 Billion, Growing 5%, and Net Income of $247 Million, or $0.50 per Diluted Share, Growing 10% and 11%, respectively, on a Reported Basis for Second Quarter 2017 Reports Adjusted Net Income of $261 Million, or Adjusted Diluted EPS of $0.53, for Second Quarter 2017 Delivers 6% Operational Growth in Revenue and 11% Operational Growth in Adjusted Net Income, Excluding Foreign Exchange, for Second Quarter 2017 Increases Full Year 2017 Revenue Guidance to $5.150 - $5.250 Billion and Diluted EPS to $2.12 - $2.21 on a Reported Basis, or $2.30 - $2.37 on an Adjusted Basis Zoetis Inc. (NYSE:ZTS) today reported its financial results for the second quarter of 2017 and increased its full year guidance for revenue and net income. The company reported revenue of $1.3 billion for the second quarter of 2017, an increase of 5% compared with the second quarter of 2016. Net income for the second quarter of 2017 was $247 million, or $0.50 per diluted share, an increase of 10% and ...
August 3, 2017
Zoetis Inc. (NYSE: ZTS) today announced the appointment of Dr. Linda Rhodes, an accomplished scientist, academic, veterinarian and business leader in animal health, to its Board of Directors. Her appointment is effective at the close of business today, and she will serve on the Quality and Innovation Committee of the Board. “I am very pleased to welcome Dr. Rhodes to the Zoetis Board of Directors,” said Zoetis Chief Executive Officer Juan Ramón Alaix. “As an experienced veterinarian, highly respected researcher and proven executive in the animal health industry, Dr. Rhodes brings a unique combination of skills and perspectives to our Board. Her experience and insights will be valuable as Zoetis navigates the changing landscape and new technologies we need to ensure our continued growth as the world leader in animal health.” Dr. Rhodes has extensive experience as a research scientist, academic, veterinary practitioner and business leader, spanning nearly 30 years across the animal ...
July 31, 2017
Acquisition strengthens pipeline of companion animal therapeutics for chronic pain, a global market estimated at US$400 million annually 1 Purchase price of US$6.72 per share, or approximately US$85 million in aggregate Zoetis Inc . (NYSE:ZTS) and Nexvet Biopharma plc (Nasdaq:NVET) today announced that Zoetis has completed the acquisition of Nexvet, a biologic therapeutics company developing a pipeline of monoclonal antibody (mAb) therapies for companion animals in pain and other therapeutic areas. The acquisition, which was first announced on April 13, 2017 , strengthens Zoetis’ pipeline of solutions for chronic pain management in dogs and cats. It became effective today by means of a scheme of arrangement under the Irish Companies Act 2014. Under the terms of the transaction, Nexvet shareholders will receive US$6.72 per share representing an aggregate equity valuation of approximately US$85 million. The Nexvet shareholders will receive the consideration to which they are entitled ...
June 30, 2017
Zoetis Inc. (NYSE:ZTS) will host a webcast and conference call at 8:30 a.m. (ET) on Tuesday, August 8, 2017. Chief Executive Officer Juan Ramón Alaix and Executive Vice President and Chief Financial Officer Glenn David will review second quarter 2017 financial results and respond to questions from financial analysts during the call. Investors and the public may access the live webcast by visiting the Zoetis website at http://investor.zoetis.com/events-presentations. Information on accessing and pre-registering for the webcast is available beginning today. A replay of the webcast will be made available on August 8, 2017. About Zoetis Zoetis is the leading animal health company, dedicated to supporting its customers and their businesses. Building on more than 60 years of experience in animal health, Zoetis discovers, develops, manufactures and markets veterinary vaccines and medicines, complemented by diagnostic products, genetic tests, biodevices and a range of services. Zoetis serves ...
June 16, 2017
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF THAT JURISDICTION. FOR IMMEDIATE RELEASE June 16, 2017 Recommended Acquisition for Cash by ZOETIS BELGIUM S.A. A WHOLLY-OWNED INDIRECT SUBSIDIARY OF ZOETIS INC. of NEXVET BIOPHARMA PUBLIC LIMITED COMPANY to be implemented by means of a scheme of arrangement
under Chapter 1 of Part 9 of the Irish Companies Act 2014 Announcement relating to dispatch of Rule 15 Letter On April 13, 2017, Nexvet Biopharma plc, a public limited company incorporated in Ireland (" Nexvet " or the " Company "), Zoetis Inc. (“ Zoetis ”) and its wholly-owned indirect subsidiary Zoetis Belgium S.A. (“ Bidco ”) announced that they had reached agreement on the terms of a recommended acquisition of Nexvet by Zoetis, through Bidco, whereby Bidco will acquire all of the issued and to be issued ordinary shares of the Company (the " ...
June 1, 2017
Zoetis Inc . (NYSE:ZTS) will participate in the William Blair Growth Stock Conference on Tuesday, June 13, 2017, in Chicago, Ill. Juan Ramón Alaix, Chief Executive Officer, will represent the company and respond to questions from analysts. He is scheduled to present at 3:10 p.m. ET (2:10 p.m. CT). Investors and other interested parties will be able to access a live audio webcast of the presentation by visiting http://investor.zoetis.com/events-presentations. A replay of the presentation will also be available on the Zoetis website at the conclusion of the event. About Zoetis Zoetis is the leading animal health company, dedicated to supporting its customers and their businesses. Building on more than 60 years of experience in animal health, Zoetis discovers, develops, manufactures and markets veterinary vaccines and medicines, complemented by diagnostic products, genetic tests, biodevices and a range of services. Zoetis serves veterinarians, livestock producers and people who raise and ...
May 25, 2017
Zoetis Inc . (NYSE:ZTS) will participate in the Stifel 2017 Dental and Veterinary Conference on Wednesday, May 31, 2017, in New York, N.Y. Kristin Peck, Executive Vice President and President, U.S. Operations, will represent the company and respond to questions from analysts. She is scheduled to present at 3:00 p.m. ET. Investors and other interested parties will be able to access a live audio webcast of the presentation by visiting http://investor.zoetis.com/events-presentations. A replay of the presentation will also be available on the Zoetis website at the conclusion of the event. About Zoetis Zoetis is the leading animal health company, dedicated to supporting its customers and their businesses. Building on more than 60 years of experience in animal health, Zoetis discovers, develops, manufactures and markets veterinary vaccines and medicines, complemented by diagnostic products, genetic tests, biodevices and a range of services. Zoetis serves veterinarians, livestock producers ...
May 11, 2017
The Board of Directors of Zoetis Inc . (NYSE:ZTS) has declared a third quarter 2017 dividend payable to holders of the company’s common stock of $0.105 per share. The dividend is to be paid on Friday, Sept. 1, 2017, to holders of record on Thursday, June 15, 2017. About Zoetis Zoetis is the leading animal health company, dedicated to supporting its customers and their businesses. Building on more than 60 years of experience in animal health, Zoetis discovers, develops, manufactures and markets veterinary vaccines and medicines, complemented by diagnostic products, genetic tests, biodevices and a range of services. Zoetis serves veterinarians, livestock producers and people who raise and care for farm and companion animals with sales of its products in more than 100 countries. In 2016, the company generated annual revenue of $4.9 billion with approximately 9,000 employees. For more information, visit www.zoetis.com . DISCLOSURE NOTICES Forward-Looking Statements: This press release ...
May 11, 2017
Speaking to shareholders at the Zoetis Inc . (NYSE:ZTS) annual meeting today in Short Hills, N.J., Chief Executive Officer Juan Ramón Alaix discussed the company’s 2016 performance and strategies for continued growth as the leader in the global animal health industry. “In 2016, we delivered our fourth consecutive year of operational revenue growth and improved profitability since becoming an independent public company,” said Alaix. “As we look to the remainder of 2017 and beyond, we have set Zoetis on a course to continue growing our industry leadership based on deep relationships with customers, highly productive innovation, and high-quality manufacturing and supply. We also remain committed to the long-term value proposition that has generated returns for our investors.” Zoetis Chairman Michael McCallister presided over the business portion of the meeting and shareholder voting. Preliminary results of shareholder voting from the meeting are as follows: Gregory Norden, Louise M. ...
May 10, 2017
Awarded Michigan Business Development Program Grant Will Add Up to 45 Manufacturing Jobs in Next Three Years Zoetis Inc. today announced a plan to expand capacity at its Global Manufacturing and Supply facility in Kalamazoo, Mich.  Zoetis will install two new production lines and related operations to manufacture oral tablet and chewable medicines for companion animals. The company expects to add up to 45 manufacturing positions in the next three years. “Kalamazoo is home to one of the largest and most important manufacturing sites in Zoetis’ Global Manufacturing and Supply network,” said Matthew Everhart, Vice President, Pharmaceutical and Aseptic Operations, Global Manufacturing and Supply at Zoetis. “Locating manufacturing here gives us continued access to a highly skilled and diverse workforce which is essential to managing a global animal health company. Our people provide our veterinarian and livestock farmer customers with a reliable supply of high quality medicines for their ...
May 9, 2017
Zoetis Inc . (NYSE:ZTS), the global leader in animal health, today announced that it has been named one of America’s Best Midsize Employers by Forbes Magazine for the second year in a row. Zoetis is the only midsize company focused on animal health to make the list. “Zoetis is honored to once again be named one of America’s Best Employers by Forbes Magazine,” said Roxanne Lagano, Executive Vice President and Chief Human Resources Officer. “We have created a distinct culture at Zoetis grounded in our Core Beliefs – a culture in which integrity, accountability, collaboration and customer focus are hallmarks of success. This culture has contributed to the growth of our company, and we are very proud that our colleagues and others recommend Zoetis as a great place to work.” Forbes determined its America’s Best Employers list based on an independent survey among a sample of 30,000 American employees working for large and midsize companies and institutions. The willingness to recommend ...
May 8, 2017
Global animal health company receives grant from the Bill & Melinda Gates Foundation to advance the health and productivity of livestock in Africa Zoetis Inc. (NYSE:ZTS), the largest global animal health company, announced it will receive a US$14.4 million grant from the Bill & Melinda Gates Foundation over the next three years to develop veterinary diagnostic networks and animal health infrastructure in Ethiopia, Nigeria and Uganda. The grant will enable Zoetis to develop veterinary laboratory networks and outreach services to increase the availability of local veterinary medicines and services; implement sustainable disease diagnostics; and strengthen local veterinary expertise. “We believe the combination of Zoetis’ leadership in animal health and experience in forging broad collaborations in emerging markets will allow us to accelerate the advancement of animal health in the region,” said Juan Ramón Alaix, Chief Executive Officer of Zoetis. “Access to medicines and ...
May 4, 2017
Reports Revenue of $1.2 Billion, Growing 6%, and Net Income of $238 Million, or $0.48 per Diluted Share, Growing 17% on a Reported Basis for First Quarter 2017 Reports Adjusted Net Income of $261 Million, or Adjusted Diluted EPS of $0.53, for First Quarter 2017 Delivers 6% Operational Growth in Revenue and 10% Operational Growth in Adjusted Net Income, Excluding Foreign Exchange, for First Quarter 2017 Reaffirms Full Year 2017 Revenue Guidance of $5.100 - $5.225 Billion and Diluted EPS of $2.08 - $2.20 on a Reported Basis, or $2.26 - $2.36 on an Adjusted Basis Zoetis Inc . (NYSE:ZTS) today reported its financial results for the first quarter of 2017 and reaffirmed its guidance for full year 2017. The company reported revenue of $1.2 billion for the first quarter of 2017, an increase of 6% compared with the first quarter of 2016. Net income for the first quarter of 2017 was $238 million, or $0.48 per diluted share, an increase of 17% on a reported basis. Adjusted net income 1 for the ...
May 2, 2017
Zoetis Inc . (NYSE:ZTS) will participate in the Bank of America Merrill Lynch Health Care Conference on Wednesday, May 17, 2017, in Las Vegas, Nev. Juan Ramón Alaix, Chief Executive Officer, will represent the company and respond to questions from analysts. He is scheduled to present at 4:00 p.m. ET (1:00 p.m. PT). Investors and other interested parties will be able to access a live audio webcast of the presentation by visiting http://investor.zoetis.com/events-presentations. A replay of the presentation will also be available on the Zoetis website at the conclusion of the event. About Zoetis Zoetis is the leading animal health company, dedicated to supporting its customers and their businesses. Building on more than 60 years of experience in animal health, Zoetis discovers, develops, manufactures and markets veterinary vaccines and medicines, complemented by diagnostic products, genetic tests, biodevices and a range of services. Zoetis serves veterinarians, livestock producers and ...
April 26, 2017
The first monoclonal antibody authorized for veterinary use in the European Union A single injection of Cytopoint treats the clinical signs of atopic dermatitis in dogs, including itch and inflammation, for up to one month Targets and neutralizes canine interleukin-31 (cIL-31), a key cytokine involved in stimulating itch in dogs with atopic dermatitis Joins Zoetis’ Apoquel ® (oclacitinib tablet), giving veterinarians two targeted treatment options for canine patients with atopic dermatitis Zoetis Inc . (NYSE:ZTS) today announced that the European Commission has granted the company marketing authorization for Cytopoint (lokivetmab), the first monoclonal antibody (mAb) therapy approved in the European Union for veterinary use. Cytopoint is indicated to treat the clinical signs, including itching and inflammation, associated with atopic dermatitis in dogs of any age weighing 3 kilograms or more. Cytopoint targets and neutralizes canine interleukin-31 (cIL-31), a key protein involved in ...
April 13, 2017
Purchase price of US$6.72 per share, or approximately US$85 million in aggregate Acquisition to strengthen Zoetis’ pipeline in companion animal therapeutics for chronic pain, a global area estimated at US$400 million annually 1 Zoetis Inc. (NYSE:ZTS) and Nexvet Biopharma plc (Nasdaq:NVET) today announced an agreement in which Zoetis, through a wholly owned subsidiary (“Zoetis Bidco”), will purchase Nexvet, an innovator in monoclonal antibody therapies for companion animals, for a purchase price of US$6.72 per share, representing an aggregate equity valuation of approximately US$85 million. The acquisition will strengthen Zoetis’ pipeline of solutions for chronic pain management in dogs and cats, which represents an area of high-need in companion animal health. This per share consideration represents a 66% premium over Nexvet’s closing price on April 12, 2017. The board of directors of Nexvet has unanimously approved the acquisition, which is being implemented by means of a scheme of ...
April 13, 2017
COMPANY NAME: ZOETIS INC. HEADLINE: ZOETIS TO ACQUIRE NEXVET FOR US$85 MILLION NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION (IN WHOLE OR IN PART) IN, INTO OR FROM ANY RESTRICTED JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF SUCH JURISDICTION FOR IMMEDIATE RELEASE 13 April 2017 ZOETIS TO ACQUIRE NEXVET FOR US$6.72 IN CASH PER SHARE Acquisition strengthens Zoetis’ R&D pipeline in biologics, including monoclonal antibodies for pain and other therapeutic areas in companion animals. Zoetis continues investing in emerging areas to fuel future growth and sustain its leadership in animal health. Parsippany, New Jersey, US and Tullamore, Ireland 13 April 2017 – Zoetis Inc. (“Zoetis”) (NYSE: ZTS) and Nexvet Biopharma plc (“Nexvet”) (NASDAQ: NVET) today announced an agreement on the terms of a recommended offer to be made by Zoetis, through a wholly-owned subsidiary, for all of the issued and to be issued ordinary shares of Nexvet for US$6.72 in ...
April 5, 2017
Zoetis launches Itch Instinct tool in support of its K-9 Courage™ Program Zoetis Inc. (NYSE:ZTS), the leading global animal health company, today announced that music and television star Nick Lachey* is teaming up with the company to launch Your Animal Instinct , a program to help your dog put its best paw forward this spring. Your Animal Instinct aims to help pet owners understand when their dog’s itching may be due to an allergy-related skin condition – and what they can do about it. During the program’s kick-off this spring allergy season, dog owners are encouraged to take an online itch quiz at YourAnimalInstinct.com to help them distinguish between their dog’s normal itch and when frequent scratching, licking, biting, and/or rubbing could be the sign of allergic skin disease. Completion of the “Itch Instinct” quiz will trigger a donation made by Zoetis to expand the number of recipients in its K-9 Courage™ Program, which provides healthcare assistance to retired military and ...
March 31, 2017
Zoetis Inc . (NYSE:ZTS) will host a webcast and conference call at 8:30 a.m. (ET) on Thursday, May 4, 2017. Chief Executive Officer Juan Ramón Alaix and Executive Vice President and Chief Financial Officer Glenn David will review first quarter 2017 financial results and respond to questions from financial analysts during the call. Investors and the public may access the live webcast by visiting the Zoetis website at http://investor.zoetis.com/events-presentations. Information on accessing and pre-registering for the webcast is available beginning today. A replay of the webcast will be made available on May 4, 2017. About Zoetis Zoetis is the leading animal health company, dedicated to supporting its customers and their businesses. Building on more than 60 years of experience in animal health, Zoetis discovers, develops, manufactures and markets veterinary vaccines and medicines, complemented by diagnostic products, genetic tests, biodevices and a range of services. Zoetis serves ...
March 21, 2017
Zoetis Inc . (NYSE:ZTS) will participate in the Jefferies Animal Health Summit on Thursday, March 30, 2017, in New York, N.Y. Juan Ramón Alaix, Chief Executive Officer, will represent the company and respond to questions from analysts. He is scheduled to present at 9:30 a.m. ET. The presentation is not scheduled to be webcast. Investors and other interested parties will be able to access the presentation materials at http://investor.zoetis.com/events-presentations at the conclusion of the event. About Zoetis Zoetis is the leading animal health company, dedicated to supporting its customers and their businesses. Building on more than 60 years of experience in animal health, Zoetis discovers, develops, manufactures and markets veterinary vaccines and medicines, complemented by diagnostic products, genetic tests, biodevices and a range of services. Zoetis serves veterinarians, livestock producers and people who raise and care for farm and companion animals with sales of its products in ...
February 17, 2017
PARSIPPANY, N.J.  – Feb. 17, 2017 - We at Zoetis are pleased that the European Medicines Agency, Committee for Veterinary Products for Medicinal Use, adopted a positive opinion for Cytopoint™ at their February meeting. Upon full approval, Cytopoint would become the first monoclonal antibody licensed for veterinary use in the European Union. It is indicated for the treatment of clinical manifestations of atopic dermatitis in dogs. Lokivetmab, the active substance in Cytopoint, is a caninised monoclonal antibody that specifically targets canine interleukin-31, a key cytokine in canine atopic dermatitis. We look forward to the decision of the European Commission on our application for marketing authorization of Cytopoint. About Zoetis Zoetis is the leading animal health company, dedicated to supporting its customers and their businesses. Building on more than 60 years of experience in animal health, Zoetis discovers, develops, manufactures and markets veterinary vaccines and ...
February 17, 2017
Zoetis Inc. (NYSE:ZTS) will participate in the Cowen and Company 37th Annual Health Care Conference on March 6, 2017, in Boston, Mass. Clint Lewis, Executive Vice President and President, International Operations at Zoetis, will represent the company and respond to questions from analysts. He is scheduled to present at 4:00 p.m. ET. Investors and other interested parties will be able to access a live audio webcast of the presentation by visiting http://investor.zoetis.com/events-presentations. A replay of the presentation will also be available on the Zoetis website at the conclusion of the event. About Zoetis Zoetis is the leading animal health company, dedicated to supporting its customers and their businesses. Building on more than 60 years of experience in animal health, Zoetis discovers, develops, manufactures and markets veterinary vaccines and medicines, complemented by diagnostic products, genetic tests, biodevices and a range of services. Zoetis serves veterinarians, ...
February 16, 2017
For Fourth Quarter 2016, Zoetis Reports Revenue of $1.3 Billion, and Net Income of $154 Million, or $0.31 per Diluted Share, on a Reported Basis Reports Adjusted Net Income of $232 Million, or Adjusted Diluted EPS of $0.47, for Fourth Quarter 2016 Delivers Flat Operational Growth in Revenue and 13% Operational Growth in Adjusted Net Income, Excluding Foreign Exchange, for Fourth Quarter 2016 For Full Year 2016, Zoetis Reports Revenue of $4.9 Billion and Net Income of $821 Million, or $1.65 per Diluted Share, on a Reported Basis Reports Adjusted Net Income of $975 Million, or Adjusted Diluted EPS of $1.96, for Full Year 2016 Delivers 5% Operational Growth in Revenue and 17% Operational Growth in Adjusted Net Income, Excluding Foreign Exchange, for Full Year 2016 Updates Full Year 2017 Revenue Guidance to $5.100 - $5.225 Billion, with Diluted EPS of $2.08 - $2.20 on a Reported Basis, or $2.26 - $2.36 on an Adjusted Basis, To Reflect Changes in Foreign Exchange Rates Zoetis Inc . ...
February 15, 2017
A new topical parasiticide for cats combines the active ingredient in Stronghold – selamectin – with sarolaner for broadened and extended spectrum of protection Company introduces first combination product building on its sarolaner platform in the $4.2 billion companion animal parasiticide market Zoetis Inc . (NYSE:ZTS) today announced that the European Commission has granted the company a license for Stronghold ® Plus (selamectin/sarolaner), a topical combination of parasiticides that treats ticks, fleas, ear mites, lice and gastrointestinal nematodes and prevents heartworm disease in cats. Veterinarians across the European Union now have a treatment choice that leverages the benefits of sarolaner, a new innovation in the class of isoxazolines, without sacrificing the broad spectrum protection, safety or ease of use they expect. ”The approval of Stronghold Plus enables Zoetis to offer veterinarians a new topical choice that treats the parasites commonly presenting a threat to cats ...
February 14, 2017
The Board of Directors of Zoetis Inc . (NYSE:ZTS) has declared a second quarter 2017 dividend payable to holders of the company’s common stock of $0.105 per share. The dividend is to be paid on Thursday, June 1, 2017, to holders of record on Thursday, April 6, 2017. About Zoetis Zoetis is the leading animal health company, dedicated to supporting its customers and their businesses. Building on more than 60 years of experience in animal health, Zoetis discovers, develops, manufactures and markets veterinary vaccines and medicines, complemented by diagnostic products and genetic tests and supported by a range of services. Zoetis serves veterinarians, livestock producers and people who raise and care for farm and companion animals with sales of its products in more than 100 countries. In 2015, the company generated annual revenue of $4.8 billion with approximately 9,000 employees. For more information, visit www.zoetis.com . DISCLOSURE NOTICES Forward-Looking Statements: This press ...
January 3, 2017
Nordland Sett Vaks is a leading fish vaccination company renowned for its high quality vaccination machines and focus on innovation • Acquisition will enable PHARMAQ to offer complete vaccination solutions • PHARMAQ to support Nordland Sett Vaks’ international expansion OSLO, NORWAY – Jan. 3, 2017 - PHARMAQ, a business of Zoetis, today announced the acquisition of the Norwegian  company Nordland Sett Vaks, an innovator in the manufacture and marketing of high quality vaccination machinery for the aquaculture industry. Nordland Sett Vaks is based in Nesna, Norway, and offers a wide range of fish vaccination services and sale of vaccination machines to fish farming companies in Norway, the UK and in the Mediterranean region. Terms of the transaction were not disclosed. “We have known Nordland Sett Vaks for a long time, and we have been very impressed with their high focus on quality and innovative solutions. We are delighted to start working even closer together with Nordland Sett Vaks ...